Jingxin Pharmaceutical (002020.SZ): The company's Cariprazine Hydrochloride Capsules are currently undergoing normal regulatory review.

Gelonghui reported on May 9 that Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform that its Cariprazine Hydrochloride Capsules are under normal review and are also included in the relevant public notice list.

Gelonghui FinanceMay 9 14:53

Orient Securities: The pharmaceuticals and biotechnology industry is expanding overseas, presenting an excellent opportunity to capitalize on contract manufacturing for innovative drugs.

Domestic centralized procurement and healthcare reform policies are gradually becoming more moderate, while international operations, after years of cultivation, have already gained momentum and continue to accelerate overseas expansion.

Zhitong FinanceMay 6 09:16

Jingxin Pharmaceutical (002020): Steady Growth in Profitability and Breakthrough Progress in Pipeline Development

Event Description: In April 2025, Jingxin Pharmaceutical (002020) released its 2025 annual report. For the full year of 2025, the company achieved operating revenue of 4.069 billion yuan (a year-on-year decrease of 2.14%) and a net profit attributable to shareholders of 7.

Changjiang SecuritiesMay 4 00:00

Jingxin Pharmaceutical (002020): Rapid scaling of Didazini and continuous advancement of innovative pipeline

Didesani quickly gained market share, with its innovative pipeline continuing to progress. The 'Buy' rating was maintained. In 2025, the company's revenue reached 4.069 billion yuan (a year-on-year decrease of 2.14%); net profit attributable to shareholders was 758 million yuan (a year-on-year increase of 6.46%); non-recurring

Open Source SecuritiesApr 28 07:47

Jingxin Pharmaceutical (002020): Steady Growth in Performance, Surpassing Expectations with the Launch of Didazini

Event: Jingxin Pharmaceutical achieved steady growth in 2025 performance, with significant results from its innovation transformation. The company reported annual revenue of 4.069 billion yuan (a year-on-year decrease of 2.14%) and net profit attributable to shareholders of 758 million yuan (a year-on-year increase of 6.46%). Excluding non-recurring items, the core profit was

Founder SecuritiesApr 24 00:00

Jingxin Pharmaceutical: 2025 Annual Report

SZSIApr 24 00:00 · Announcements